


Summary

In one aspect, the present disclosure relates to the compound of formula (I)




wherein

- 5 R¹ is hydrogen or C₁₋₇-alkyl;
- R² is hydrogen, cyano, C₁₋₇-alkyl, C₁₋₇-haloalkyl or C₃₋₈-cycloalkyl;
- R³ is hydrogen, C₁₋₇-alkyl, or C₃₋₈-cycloalkyl;
- A is N-heterocycloalkyl or NR¹²R¹³, wherein N-heterocycloalkyl comprises 1 or 2
10 nitrogen ring atoms and is optionally substituted with 1, 2, 3 or 4 substituents
 selected from R¹⁴;
- R¹² is heterocycloalkyl comprising 1 nitrogen ring atom, wherein heterocycloalkyl is
 optionally substituted with 1, 2, 3 or 4 substituents selected from R¹⁴;
- R¹³ is hydrogen, C₁₋₇-alkyl or C₃₋₈-cycloalkyl;
- 15 R¹⁴ is independently selected from hydrogen, C₁₋₇-alkyl, amino, amino-C₁₋₇-alkyl, C₃₋₈-
 cycloalkyl and heterocycloalkyl or two R¹⁴ together form C₁₋₇-alkylene;

with the proviso that if A is N-heterocycloalkyl comprising only 1 nitrogen ring atom, then
at least one R¹⁴ substituent is amino or amino-C₁₋₇-alkyl;

and pharmaceutically acceptable salts thereof.

In another aspect, the present disclosure relates to the compound of formula (VI)



wherein R¹, R² and R³ are as described herein;

Y is halogen or trifluoromethanesulfonate;

5 and salts thereof.

In another aspect, the present disclosure relates to a process for the preparation of compounds of formula (I) as disclosed herein, comprising an aromatic nucleophilic substitution reaction between a compound of formula (VI) as described herein with a compound of formula M-A by heating in a solvent, wherein A, R¹, R² and R³ are as defined herein, Y is as defined
10 herein, M is hydrogen, sodium or potassium, and wherein M is linked to A via a nitrogen atom of A.

In another aspect, the present disclosure relates to compounds of formula (I) as disclosed herein obtainable by a process as disclosed herein.

In another aspect, the present disclosure relates to pharmaceutical compositions comprising
15 compounds of formula (I) as disclosed herein or their pharmaceutically acceptable salts and one or more pharmaceutically acceptable excipients.

In another aspect, the present disclosure relates to compounds of formula (I) as disclosed herein or their pharmaceutically acceptable salts above for use as therapeutically active substances.

20 In another aspect, the present disclosure relates to compounds of formula (I) as disclosed herein or their pharmaceutically acceptable salts for the use in the treatment or prevention of spinal muscular atrophy (SMA).

In another aspect, the present disclosure relates to the use of compounds of formula (I) as disclosed herein or their pharmaceutically acceptable salts for the preparation of medicaments
25 for the treatment or prevention of spinal muscular atrophy (SMA).

53. The use of compounds of formula (I) according to any of claims 1 - 40 or their pharmaceutically acceptable salts for the preparation of medicaments for the treatment or prevention of spinal muscular atrophy (SMA).